Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1026 - Gene expression signatures in BRAF V600E mutant colorectal cancer in relation to WNT signaling cascade

Date

09 Sep 2017

Session

Poster display session

Presenters

KAZUYA YASUI

Citation

Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393

Authors

K. YASUI1, T. Nagasaka1, A. Nyuya1, T. Toshima1, T. Kawai1, K. Shigeyasu1, S. Yano1, Y. Mori1, J. Haraga2, K. Nakamura2, Y. Umeda1, A. Goel3, T. Fujiwara1

Author affiliations

  • 1 Gastroenterological Surgery, Okayama University Hospital, 700-8558 - Okayama/JP
  • 2 Department Of Obstetrics And Gynecology, Okayama University Hospital, 700-8558 - Okayama/JP
  • 3 Center For Gastrointestinal Research Center For Translational Genomics And Oncology, CeBaylor Scott & White Research Institutenter for Translational Genomics and Oncology, 75246 - Texas/US
More

Resources

Abstract 1026

Background

Colorectal cancers (CRC) with BRAF V600E mutations have typically shown poor outcomes in several clinical trials, but its biological role has not been fully elucidated. Classification of CRCs according to gene expression profiling and methylome analysis remains controversial with regards to their ability to stratify patients for precision therapy.

Methods

We performed mRNA microarray analysis and used pathway analyses by Gene Set Enrichment Analysis (GSEA) in the following three subsets; eight BRAF-mutant CRC tissues without MSI, six BRAF-mutant CRCs with MSI and five BRAF-wild type CRCs with MSI. Following identification of candidate biomarkers that affect poor outcomes and associate with BRAF V600E mutation, we examined epigenetic variations of these candidate biomarkers in a cohort of 1068 CRC patients who underwent surgical resection of their primary tumor and/or metastatic lesions from 1994 to 2015 at the Okayama University Hospital.

Results

Prominent signatures enriched in CRCs with BRAF V600E mutation were EMT-related processes (EMT and myogenesis), Wnt signaling and intestinal differentiation-related genes. Among the differentially expressed genes, Wnt-antagonist, Secreted frizzled-related proteins (SFRPs) were significantly upregulated in CRCs with BRAF V600E mutation especially without MSI. As SFRPs are well known to be inactivated by promoter hypermethylation, and up to 80% of CRCs are methylated in the promoter region of the SFRP2 gene, we speculated and analyzed SFRP2 promoter methylation status in 993 CRCs of our cohort by a modified highly sensitive assay for bisulfite DNA followed by fluorescence-based PCR, as we previously reported (JNCI 2009). SFRP2 methylation was observed in 647 (65.2%). Interestingly, SFRP2 unmethylated CRCs with genetic mutation in the KRAS/BRAF genes demonstrated significantly poorer outcome in RFS compared with SFRP2 methylated CRCs with genetic mutations in the KRAS/BRAF genes (5-yrs RFS: 59.0% vs 80.4%, P 

Conclusions

Our results suggest that SFRP2 methylation status could be a potential prognostic biomarker for CRCs, especially with genetic mutations in the KRAS/BRAF genes.

Clinical trial identification

Legal entity responsible for the study

Department of Gastroenterological Surgery, Okayama University

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.